10.6084/m9.figshare.8172743.v1 Mark Stein Mark Stein Jyoti Malhotra Jyoti Malhotra Rohinton Tarapore Rohinton Tarapore Usha Malhotra Usha Malhotra Ann Silk Ann Silk Nancy Chan Nancy Chan Lorna Rodriguez Lorna Rodriguez Joseph Aisner Joseph Aisner Robert Aiken Robert Aiken Tina Mayer Tina Mayer Bruce Haffty Bruce Haffty Jenna Newman Jenna Newman Salvatore Aspromonte Salvatore Aspromonte Praveen Bommareddy Praveen Bommareddy Ricardo Estupinian Ricardo Estupinian Charles Chesson Charles Chesson Evita Sadimin Evita Sadimin Shengguo Li Shengguo Li Daniel Medina Daniel Medina Tracie Saunders Tracie Saunders Melissa Frankel Melissa Frankel Aparna Kareddula Aparna Kareddula Sherrie Damare Sherrie Damare Elayne Wesolowsky Elayne Wesolowsky Christian Gabel Christian Gabel Wafik El-Deiry Wafik El-Deiry Varun Prabhu Varun Prabhu Joshua Allen Joshua Allen Martin Stogniew Martin Stogniew Wolfgang Oster Wolfgang Oster Joseph Bertino Joseph Bertino Steven Libutti Steven Libutti Janice Mehnert Janice Mehnert Andrew Zloza Andrew Zloza Additional file 1: of Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration Springer Nature 2019 ONC201 Cancer Solid tumors Immunotherapy Immuno-oncology Dopamine 2019-05-22 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Safety_and_enhanced_immunostimulatory_activity_of_the_DRD2_antagonist_ONC201_in_advanced_solid_tumor_patients_with_weekly_oral_administration/8172743 Figure S1. Ratio of cleaved:total cytokeratin 18 (M30/M65 ELISA assay) in patients treated with weekly ONC201. Figure S2. Maximum fold change over baseline of immune cytokines and effector molecules in all ONC201-treated patients in the two dosing cohorts (every three weeks and weekly dosing schedules). Figure S3. (A) Maximum fold change of serum prolactin levels in the serum relative to baseline when compared to maximum concentration of ONC201 in the serum of the patients treated on a weekly schedule. Figure S4. Maximum fold induction of caspase-cleaved cytokeratin 18 levels in the serum relative to baseline when compared to maximum concentration of ONC201 in the serum of the patients treated on a weekly schedule. Figure S5. Timing of maximum fold-induction of immune cytokines and effects. Figure S6. Serum PSA (ng/mL) of ONC201-treated prostate cancer patients. Table S1. Treatment-related adverse events (AEs) in patients treated with ONC201 on a weekly schedule. Table S2. Pharmacokinetic parameters for 625 mg of ONC201 after the first dose of cycle 1 and after the first dose of cycle 2 (n = 17). (DOCX 324 kb)